Meta AnalysisID 6732
参苓白术散治疗肥胖合并2型糖尿病的有效性与安全性：一项系统评价与Meta分析
CRD42023450166
Efficacy and Safety of Shenling Baizhu San in treating obesity combined with type 2 diabetes mellitus：A Systematic Review and Meta-Analysis
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6732
- Evidence Id
- 15290
- Core Evidence Id
- 15290
- Source Meta Analysis Id
- 6716
- Herb2 Meta Analysis Id
- HBMA006716
- Crd Id
- CRD42023450166
- Title
- Efficacy and Safety of Shenling Baizhu San in treating obesity combined with type 2 diabetes mellitus：A Systematic Review and Meta-Analysis
- Review Question
- Efficacy and Safety of Shenling Baizhu San in treating obesity combined with type 2 diabetes mellitus：A Systematic Review and Meta-Analysis
- Study Type Included
- All randomized controlled trials of Shenling Baizhu San in treating obesity combined with type 2 diabetes mellitus were included.The gender and age of patients were not limited.The exclusion criteria were as follows: studies with incomplete or incorrect data, experimental group or control group combined with other TCM during treatment, and Animal experiments and review literature.
- Condition Being Studied
- Obesity is a chronic metabolic disease caused by excessive body fat accumulation due to higher body calorie intake than consumption, and the measured body mass rate is far beyond the standard body mass rate .Various concurrent diseases with obesity, such as type 2 diabetes mellitus (T2DM), hypertension, atherosclerosis, also affect and disturb people’s health and life . Obesity, as a prodrome, is a significant factor in T2DM pathogenesis . Currently, most obese patients with T2DM are treated with metformin, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors..In recent years, clinical studies on using TCM to treat obesity combined with T2DM have emerged gradually, and the increasing number of clinical observations have demonstrated their good efficacy in reducing body mass index, improving insulin resistance, and correcting maladjusted endocrine function .
- Participant
- Patients enrolled in this study were all diagnosed with T2DM combined with obesity and had established diagnostic criteria; obesity was defined as body mass index (BMI) > 28 kg/m2 ; regardless of gender, age, race or course of disease.The intervention plan of treatment group included simple Shenling Baizhu San, or Shenling Baizhu San combined with Western medicine. The outcome indicators should include at least one of the following: total effective rate, body mass index (BMI), fasting plasma glucose (FPG), haemoglobin A1c (HbA1C)), triglyceride (TG), waist circumference, and body fat rate.The exclusion criteria were as follows: studies with incomplete or incorrect data, experimental group or control group combined with other TCM during treatment, and Animal experiments and review literature.
- Animal
- Human Disease Modelled
- Intervention
- The control group will include Western medicine protocols, while interventional group will include Shenling Baizhu San(SLBZ) treatment protocols. There will be no limitations on SLBZ dosage, treatment, or manufacturer. The interventional group or control group combined with other TCM during treatment were excluded .
- Comparator Control
- The control group will include western medicine protocols, such as oral Metformin, Glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase 4 (DPP-4) inhibitor.
- Main Outcome
- Main outcomes included effective rate of clinical symptoms, body mass index (BMI), and fasting plasma glucose (FPG). Measures of effect
- Outcome Measure
- Additional Outcome
- Additional outcomes included measurement of blood glucose levels (such as haemoglobin A1c (HbA1C)), measurement of obesity levels (such as triglyceride (TG), waist circumference, and body fat rate)).
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Baizhu; Diabetes Mellitus, Type 2; Humans
- Contact
- Jinlin Huo [email protected]
- Organisational Affiliation
- Institute of Precision Medicine, The First Affiliated Hospital of Shantou University Medical College https://www.stuh.com.cn/
- Funding Source
- Youth Project of National Natural Science Foundation of China, Shandong Medical and Health Technology Development Fund, Shandong Province Traditional Chinese Medicine Science and Technology Project Grant number(s) State the funder, grant or award number and the date of award Youth Project of National Natural Science Foundation of China (82101602), Shandong Medical and Health Technology Development Fund (202103070325), Shandong Province Traditional Chinese Medicine Science and Technology Project (M-2022216)
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-07-31
- Registration Date
- 2023-08-14
- Anticipated Start Date
- 2023-07-30
- Anticipated Completion Date
- 2023-12-31
- Title Cn
- 参苓白术散治疗肥胖合并2型糖尿病的有效性与安全性：一项系统评价与Meta分析
- Title En
- Efficacy and Safety of Shenling Baizhu San in treating obesity combined with type 2 diabetes mellitus：A Systematic Review and Meta-Analysis
- Bilingual Status
- complete